CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 17 enrolled
Drug / intervention
Belimumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02347891
NCT02347891Phase 3Completed
CompareCT.gov

Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis

Northwell Health·interventional·Posted Jan 28, 2015·Updated Feb 9, 2024

In Brief

A Phase 3 clinical trial evaluating Belimumab and Placebo for Myositis. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The goal of the trial is to evaluate the efficacy and safety of belimumab as a maintenance therapy in adults with refractory Idiopathic inflammatory myositis (IIM) as compared with standard of care. This is a multicentre double-blind, placebo-controlled trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyositis
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 28, 2015
Enrollment StartJan 1, 2015
Primary CompletionNov 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 11.4 years ago

Interventions

Belimumabdrug

Randomized phase: Week 0 - Week 40

Placebodrug

Randomized phase: Week 0 - Week 40